Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Dr. Reddy's Laboratories Limited

Healthcare IN DRREDDY

1268.2INR
4.90(0.39%)

Last update at 2026-06-04T09:46:00Z

Day Range

1248.401274.90
LowHigh

52 Week Range

1013.571377.26
LowHigh

Fundamentals

  • Previous Close 1263.30
  • Market Cap1004813.29M
  • Volume818986
  • P/E Ratio17.16
  • Dividend Yield0.64%
  • EBITDA88670.00M
  • Revenue TTM342149.01M
  • Revenue Per Share TTM410.87
  • Gross Profit TTM 193082.00M
  • Diluted EPS TTM70.34

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Income before tax 76784.00M 71870.00M 60485.00M 32298.00M 28324.00M
Minority interest -701.00000M 0.00000M - - -
Net income 56544.00M 55684.00M 45073.00M 23568.00M 19149.00M
Selling general administrative 93870.00M 77201.00M 46466.00M 46466.00M 54559.00M
Selling and marketing expenses - - 59465.00M 59465.00M -
Gross profit 190428.00M 163607.00M 169302.00M 113840.00M 103077.00M
Reconciled depreciation 17058.00M 14841.00M 12502.00M 11824.00M 12796.00M
Ebit 73031.00M 65588.00M 62612.00M 40818.00M 36062.00M
Ebitda 88840.00M 79286.00M 75114.00M 52642.00M 48858.00M
Depreciation and amortization 15809.00M 13698.00M 12502.00M 11824.00M 12796.00M
Non operating income net other - - - - -
Operating income 71843.00M 67729.00M 57144.00M 29476.00M 26191.00M
Other operating expenses 253692.00M 211435.00M 194192.00M 177353.00M 156763.00M
Interest expense 2829.00M 1711.00M 1428.00M 958.00M 970.00M
Tax provision 19539.00M 16186.00M 15412.00M 8730.00M 9175.00M
Interest income 2677.00M 2278.00M 1058.00M 255.00M 1653.00M
Net interest income -152.00000M 567.00M -1428.00000M 2119.00M 1653.00M
Extraordinary items - - - 44.00M 313.00M
Non recurring - - - - -
Other items - - - - -
Income tax expense 19539.00M 16186.00M 15412.00M 8730.00M 9175.00M
Total revenue 325535.00M 279164.00M 245879.00M 214391.00M 189722.00M
Total operating expenses 118585.00M 95878.00M 117615.00M 76802.00M 70118.00M
Cost of revenue 135107.00M 115557.00M 76577.00M 100551.00M 86645.00M
Total other income expense net 4941.00M 4141.00M 10226.00M -6859.00000M -6288.00000M
Discontinued operations - - - - -
Net income from continuing ops 57245.00M 55684.00M 45073.00M 23568.00M 19149.00M
Net income applicable to common shares 56551.00M 55779.00M 45073.00M 23568.00M 17238.00M
Preferred stock and other adjustments - - - - -
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Total assets 492989.00M 387518.00M 322851.00M 296654.00M 265491.00M
Intangible assets 96803.00M 36951.00M 30724.00M 27246.00M 35648.00M
Earning assets - - - - -
Other current assets 30699.00M 22729.00M 15120.00M 13902.00M 14509.00M
Total liab 155823.00M 106968.00M 89990.00M 106127.00M 90510.00M
Total stockholder equity 333388.00M 280550.00M 232861.00M 190527.00M 174981.00M
Deferred long term liab - - - - -
Other current liab 86763.00M 56685.00M 48862.00M 41595.00M 33514.00M
Common stock 834.00M 834.00M 833.00M 832.00M 832.00M
Capital stock 834.00M 834.00M 833.00M 832.00M 832.00M
Retained earnings 315793.00M 265257.00M 215593.00M 175712.00M 157934.00M
Other liab - - - 2539.00M 2739.00M
Good will 11810.00M 4253.00M 5474.00M 4418.00M 4568.00M
Other assets 19172.00M 11745.00M 7124.00M 9152.00M 11582.00M
Cash 14654.00M 7107.00M 5779.00M 14852.00M 14829.00M
Cash and equivalents 2507.00M 2600.00M 2928.00M 2310.00M 8776.00M
Total current liabilities 130392.00M 96039.00M 85721.00M 97842.00M 81472.00M
Current deferred revenue - 1435.00M 1981.00M 2576.00M 2033.00M
Net debt 32112.00M 12913.00M 7693.00M 18993.00M 15479.00M
Short term debt 38902.00M 14030.00M 12194.00M 28099.00M 24009.00M
Short long term debt 38045.00M 12723.00M 12194.00M 28099.00M 24009.00M
Short long term debt total 46766.00M 20020.00M 13472.00M 33845.00M 30308.00M
Other stockholder equity 8869.00M 9774.00M -217312.00000M -177299.00000M -158181.00000M
Property plant equipment 96978.00M 75997.00M 66294.00M 62169.00M 57111.00M
Total current assets 250112.00M 248049.00M 204255.00M 181106.00M 148249.00M
Long term investments 15202.00M 5255.00M 6089.00M 7986.00M 8333.00M
Net tangible assets - - - 158863.00M 132846.00M
Short term investments 43254.00M 74363.00M 60969.00M 29513.00M 19744.00M
Net receivables 90420.00M 80298.00M 72485.00M 70049.00M 52386.00M
Long term debt 3800.00M 3800.00M 0.00000M 5746.00M 6299.00M
Inventory 71085.00M 63552.00M 48670.00M 50884.00M 45412.00M
Accounts payable 20053.00M 21547.00M 22684.00M 25572.00M 21916.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 7892.00M 4685.00M 1266.00M 1059.00M 1326.00M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -1967.00000M
Accumulated amortization - - - - -
Non currrent assets other 21301.00M 5350.00M 12715.00M 948.00M 952.00M
Deferred long term asset charges - - - - -
Non current assets total 242877.00M 139469.00M 118596.00M 115548.00M 117242.00M
Capital lease obligations 4921.00M 3497.00M 1278.00M 2963.00M 3363.00M
Long term debt total 7864.00M 5990.00M 1278.00M 5746.00M 6299.00M
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Investments -58077.00000M -40283.00000M -41371.00000M -11201.00000M 4110.00M
Change to liabilities - - - 4412.00M 2861.00M
Total cashflows from investing activities -51021.00000M -40283.00000M -41373.00000M -26387.00000M -22660.00000M
Net borrowings 23196.00M 4346.00M - 2735.00M 6094.00M
Total cash from financing activities 11855.00M -3763.00000M -26861.00000M -2422.00000M -298.00000M
Change to operating activities - - - 4014.00M -3258.00000M
Net income 56544.00M 55684.00M 60485.00M 23568.00M 19149.00M
Change in cash 7486.00M 1328.00M -9073.00000M 32.00M 12858.00M
Begin period cash flow 7107.00M 5779.00M 14852.00M 14820.00M 1962.00M
End period cash flow 14593.00M 7107.00M 5779.00M 14852.00M 14820.00M
Total cash from operating activities 46428.00M 45433.00M 58873.00M 28108.00M 35703.00M
Issuance of capital stock 193.00M 805.00M 368.00M 334.00M 269.00M
Depreciation 17058.00M 14841.00M 12502.00M 11824.00M 12796.00M
Other cashflows from investing activities 29579.00M 1792.00M -30050.00000M 873.00M 1220.00M
Dividends paid 6662.00M 6648.00M -4979.00000M -4146.00000M -4147.00000M
Change to inventory -12753.00000M -18445.00000M -2654.00000M -5328.00000M -9881.00000M
Change to account receivables -10283.00000M -8054.00000M -5752.00000M -17012.00000M 2081.00M
Sale purchase of stock -1389.00000M 805.00M 647.00M 451.00M -1193.00000M
Other cashflows from financing activities 21200.00M -2266.00000M -21882.00000M 1724.00M 9270.00M
Change to netincome - - - 6630.00M 13866.00M
Capital expenditures 27504.00M 27435.00M 18864.00M 19049.00M 12561.00M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -30329.00000M -20182.00000M -7855.00000M -13914.00000M -8288.00000M
Stock based compensation 424.00M 407.00M 397.00M 592.00M 584.00M
Other non cash items 2731.00M -21503.00000M -21956.00000M -2692.00000M 2287.00M
Free cash flow 18924.00M 17998.00M 40009.00M 9059.00M 23142.00M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (INR) Price (INR) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
DRREDDY
Dr. Reddy's Laboratories Limited		 4.90 0.39% 1268.20 17.16 21.93 2.94 2.89 2.99 10.39
SUNPHARMA
Sun Pharmaceutical Industries Limited		 -7.0 0.39% 1781.50 40.32 26.95 7.69 5.50 7.41 23.64
DIVISLAB
Divi's Laboratories Limited		 21.00 0.32% 6597.50 70.47 - 17.47 11.44 17.33 47.08
TORNTPHARM
Torrent Pharmaceuticals Limited		 -33.1001 0.76% 4335.40 63.48 56.50 11.13 16.39 11.65 35.91
CIPLA
Cipla Limited		 24.70 1.80% 1399.90 21.74 19.01 4.23 3.76 4.08 14.00

Reports Covered

Stock Research & News

View All

Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; and research and development of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Dr. Reddy's Laboratories Limited

8-2-337, Road No. 3, Hyderabad, India, 500034

Key Executives

Name Title Year Born
Mr. Gunupati Venkateswara Prasad B.E. Co-Chairman, MD & Member of Management Council 1960
Mr. Kallam Satish Reddy B.Tech., M.S. Chairman & Member of the Management Council 1967
Mr. Erez Israeli M.B.A. CEO & Member of the Management Council 1968
Mr. Parag Agarwal CFO & Member of Management Council 1966
Mr. Deepak Sapra M.B.A. CEO of API & Services & Member of Management Council 1975
Mr. Venkata Ramana Motupalli M.B.A., MBA CEO of Branded Markets - India & Emerging Countries and Member of Management Council 1969
Ms. Archana Bhaskar B.Sc., M.B.A. EVP, Head of Corp. Communications, Chief HR Officer & Member of Management Council 1967
Mr. Sanjay Sharma B.Tech. Exec. VP, Global Head of Global Manufacturing & Member of Management Council 1968
Mr. Marc Kikuchi B.A., M.B.A. CEO of North America Generics & Member of Management Council 1969
Mr. Patrick Aghanian B.A., M.B.A. CEO of European Generics & Member of Management Council 1965

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions